DBV Technologies

DBV is proud to sponsor the Florida Allergy, Asthma, and Immunology Society 2024 Annual Meeting in Orlando! Stop by our booth to learn more about our clinical trials involving #PeanutAllergy. Learn more here: https://bit.ly/3WpeQDP #FAAIS2024

At this year's Global Food Allergy Prevention Summit, we shared a poster highlighting the open-label extension of our EPITOPE trial, as well as a poster on our Phase 3 VITESSE trial, both in #PeanutAllergy. More here: https://bit.ly/3zSSMZ6

Summer is in full swing! Keep your 4th of July BBQ #FoodAllergy safe with these tips: ☀️ Provide labels or markers to write names on cups to prevent mix-ups ☀️Clearly label dishes that contain allergens, if present ☀️ Clean your grill thoroughly and wipe down tables, chairs, toys, and cooking surfaces to remove traces of food Learn more here: https://bit.ly/3P2decM

The DBV team is a proud sponsor of the Global Food Allergy Prevention Summit in Chicago. We will be presenting data from our open-label extension study in peanut-allergic toddlers and the study design for VITESSE in 4-7-year-olds. Don't forget to come visit our booth! Info here: https://bit.ly/4c1Kywg

Epicutaneous immunotherapy (EPIT) is a new class of non-invasive treatment under investigation that seeks to modify an individual's food allergy by re-educating the immune system to become desensitized to allergens. Discover our promising preclinical research leveraging the skin's immune tolerizing properties here: https://bit.ly/4b5svUE

DBV is proud to be a sponsor at the Pennsylvania Allergy & Asthma Association (PAAA) 75th Annual Meeting. Visit our booth to learn about our Phase 3 #ClinicalTrial in children with #PeanutAllergy. More info here: https://bit.ly/3VKbRVX

Pediatric allergist Dr. Douglas Mack and Sarah Koreishi, mother of a peanut-allergic child, discussed the impact and prevalence of childhood peanut allergy, and our ongoing VITESSE clinical trial in peanut-allergic children 4-7 years old. Watch CW39 Houston for more: https://bit.ly/3KKhFbM

This week we're participating in American College of Allergy, Asthma and Immunology (ACAAI)'s Corporate Council meeting. We look forward to collaborating with allergists, immunologists and other industry leaders to engage in joint problem-solving and explore opportunities to improve patient care for children living with #FoodAllergies.

DBV Technologies presented a poster at #EAACICongress2024 on data related to its lead product candidate for peanut allergy and accidental peanut consumption. Learn more: https://bit.ly/4ckCTbY

Join DBV Technologies at the #EAACICongress2024 in Valencia, Spain. There are multiple opportunities to learn about our investigational product for treatment of #PeanutAllergy. Visit us at booth F10 to learn more: https://lnkd.in/eaPh8vSd #EAACI European Academy of Allergy and Clinical Immunology - EAACI